-
Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies
•
Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer therapy, has received marketing approval from the US Food and Drug Administration (FDA) for its Optune Lua device. This portable device is now cleared for use in combination with PD-1/PD-L1 inhibitors or docetaxel to treat…
-
Novocure Restructures and Prioritizes Pipeline Amid Anticipated NSCLC Approval
•
Novocure (NASDAQ: NVCR), a Switzerland-based developer of Tumor Treating Fields (TTFields) cancer therapeutic technology that uses electric fields to target and eliminate cancer cells, is undergoing a strategic restructuring and portfolio prioritization. The company plans to release 200 staff members, representing approximately a 13% reduction in its workforce, with the…
